The Technical Analyst
BioRestorative Therapies, [BRTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BioRestorative Therapies, Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.60% $1.440
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 9.75 mill |
| EPS: | -3.42 |
| P/E: | -0.420 |
| Earnings Date: | May 12, 2024 |
| SharesOutstanding: | 6.77 mill |
| Avg Daily Volume: | 0.668 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.420 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.07x |
| Company: PE -0.420 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.149 (-89.63%) $-1.291 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.332 - 1.548 ( +/- 7.50%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-09 | Silva Francisco | Buy | 6 600 | Common Stock |
| 2024-04-08 | Silva Francisco | Buy | 1 232 | Common Stock |
| 2024-04-08 | Silva Francisco | Buy | 476 | Common Stock |
| 2024-03-18 | Silva Francisco | Sell | 17 193 | Common Stock |
| 2024-03-18 | Alstodt Lance | Sell | 17 633 | Common Stock |
| INSIDER POWER |
|---|
| 92.40 |
| Last 100 transactions |
| Buy: 3 137 680 | Sell: 202 619 |
Forecast:
16:00 - $1.440
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.440
Forecast 2: 16:00 - $1.440
Forecast 3: 16:00 - $1.440
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.440 (3.60% ) |
| Volume | 0.244 mill |
| Avg. Vol. | 0.668 mill |
| % of Avg. Vol | 36.54 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BRTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BRTX
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
Last 10 Buy Signals
Latest Press Releases
2024-04-16 07:45:00 - Press Release
Biorestorative Therapies Announces Fda Clearance Of Phase 2 Brtx-100 Clinical Study Protocol Amendment
— amendment replaces saline injections with sham injections in the control group — melville, n.y., april 16, 2024 (globe newswire) -- biorestorative therapies, inc.
2024-04-08 07:45:00 - Press Release
Biorestorative Therapies Partners With Galen Patient Recruitment To Accelerate Completion Of Enrollment In Phase 2 Trial Of Brtx-100 In Chronic Lumbar Disc Disease
— collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity —
2024-04-03 16:38:00 - Press Release
Biorestorative Therapies Announces Filing Of Form S-1 Registration Statement To Register For Resale Common Stock Underlying Previously Issued Warrants
- company is not offering shares pursuant to the registration statement - melville, n.y., april 03, 2024 (globe newswire) -- biorestorative therapies, inc. (“biorestorative”, “brtx” or the “company”) (nasdaq: brtx ), a clinical stage company focused on stem cell-based therapies, today announced the filing of a registration statement on form s-1 with the securities and exchange commission (the “sec”).
2024-04-01 07:45:00 - Press Release
Biorestorative Therapies Announces Filing Of 2023 Annual Report On Form 10-k
Melville, n.y., april 01, 2024 (globe newswire) -- biorestorative therapies, inc. (“biorestorative”, “brtx” or the “company”) (nasdaq: brtx ), a clinical stage company focused on stem cell-based therapies, announced today the filing of its form 10-k annual report with the securities and exchange commission ("sec") for the year ended december 31, 2023.
2024-03-11 16:15:00 - Press Release
Biorestorative Therapies To Participate In The 36th Annual Roth Conference
Melville, n.y., march 11, 2024 (globe newswire) -- biorestorative therapies, inc . (“biorestorative” or the “company”) (nasdaq: brtx ), a clinical stage company focused on stem cell-based therapies, today announced its participation in the 36th annual roth conference being held march 17-19, 2024 at the ritz carlton, laguna niguel in dana point, california
Latest News
2024-02-01 07:30:00 - GlobeNewsWire
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — — Company to host webcasted conference call to review data on February 5, 2024 at 8:30am EST — MELVILLE, N.Y., Feb. 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc.
2023-07-26 12:01:38 - GuruFocus
Insider Buying Alert: Lance Alstodt Acquires 4200 Shares of BioRestorative Therapies Inc (BRTX)
On July 25, 2023, Lance Alstodt, President, CEO, COB, and 10% Owner of BioRestorative Therapies Inc ( BRTX , Financial), made a significant purchase of 4200 shares of the company's stock. This move is noteworthy as insider buying can often be a positive indicator for the company's future performance.
2023-06-16 07:00:00 - GlobeNewsWire
BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
MELVILLE, NY., June 16, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
2023-03-02 10:02:06 - PennyStocks
5 Penny Stocks To Watch With Big News This Week
Penny stocks to watch with news. The post 5 Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-01-17 09:29:00 - Newsfile Corp
BioRestorative Therapies to Present in The Jan 26th Virtual Investor Summit Microcap Event
Melville, New York--(Newsfile Corp. - January 17, 2023) - BioRestorative Therapies (NASDAQ: BRTX) ("BioRestorative", "BRTX" or the "Company"), a clinical stage company focused on stem cell-based therapies, announced today that management will be presenting at the virtual Investor Summit. During the presentation, BioRestorative Therapies Chief Executive Officer, Lance Alstdot, will highlight the Company's regenerative medicine platform and technology.
2022-09-28 07:00:00 - GlobeNewsWire
BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference
MELVILLE, NY., Sept. 28, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will be presenting at the Dawson James Securities 7th Annual Small Cap Growth Conference on October 12, 2022 at the Wyndham Grand Hotel in Jupiter, Florida.
2022-01-06 15:52:52 - PennyStocks
4 Top Penny Stocks To Buy Right Now According To Insiders
Insiders decided to buy these penny stocks recently The post 4 Top Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-01-06 06:00:00 - GlobeNewsWire
BioRestorative Therapies to Present at H.C. Wainwright BioConnect Virtual Conference
MELVILLE, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on stem cell-based therapies, today announced that Lance Alstodt, its Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually from January 10-13, 2022.
2021-12-23 09:55:11 - PennyStocks
Best Penny Stocks to Buy in January 2022? Check These 3 Out
Check these penny stocks out for your January 2022 watchlist The post Best Penny Stocks to Buy in January 2022? Check These 3 Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-12-22 06:39:57 - Pulse2
BioRestorative Therapies Stock (BRTX): Why The Price Surged Today
The stock price of BioRestorative Therapies Inc (NASDAQ: BRTX) increased by over 45% pre-market today. This is why it happened.